What FDA's PCAC briefing documents actually propose

The agency published its position before the meeting. It is worth reading directly.

TL;DR

• FDA proposes that all seven peptides under review not be added to the 503A Bulks List.
• The proposal covers both chemical forms of each substance — fourteen entries in total.
• This is a staff proposal and committee advice, not a final rule or an access change.

What the PCAC briefing documents say about peptides

FDA proposes that none of the seven peptides be included on the 503A Bulks List. That language appears in the "Points to Consider" section of the agency's briefing document, which lists each substance in both its free base and acetate form (FDA Briefing Document, 2026). Fourteen entries, fourteen proposals not to include.

A briefing document is the agency's homework, published before the meeting.

Which peptides is the PCAC reviewing in July 2026

The meeting runs July 23-24, 2026 and splits the substances across two days. On July 23 the committee discusses BPC-157, KPV, TB-500, and MOTS-c. On July 24 it discusses Emideltide (also called DSIP, in plain English: a sleep-related peptide), Epitalon, and Semax (FDA Advisory Committee Calendar, 2026).

Each substance was reviewed against a named use. TB-500 was evaluated for wound healing, MOTS-c for obesity and osteoporosis, Epitalon for insomnia.

How the evaluation works

FDA weighs four criteria set by a 2019 final rule. How well is the substance chemically characterized? What safety issues does its use raise? What evidence of effectiveness exists? And how has it historically been used in compounding? The agency applies these as a balancing test.

Think of it as four gauges read together rather than a single pass-fail score. A thin record on one gauge is not automatically disqualifying, but it has to be offset elsewhere.

Does a PCAC recommendation change peptide access

It does not. Advisory committees provide independent, non-binding advice, and FDA generally follows their recommendations but is not legally bound to do so. The agency states plainly that it does not intend to issue a final determination until committee input is considered and all reviews are finalized.

There is also a detail worth noting. Several nominations were withdrawn by the nominators, including Wells Pharmacy Network and LDT Health Solutions on behalf of the International Peptide Society. FDA elected to proceed with the presentations anyway.

What to know before drawing conclusions

Nothing about current access changes because a briefing document published. A substance's compounding status changes through formal rulemaking, not through a meeting agenda or a committee vote. Headlines that treat a proposal as a decision are moving faster than the process does.

The Halftime POV

We read the primary documents rather than the coverage of them, and we tell you what they say even when the direction is unwelcome. The honest read here is that FDA's stated position going into this meeting is restrictive. We update our formulary when rules actually change, never in anticipation of them.

Related reading:

• PCAC July 2026 meeting: what the advisory committee is reviewing
• The PCAC advisory committee explained
• The FDA 503A bulks list, explained
• Why some peptides are still Category 2
• 12 peptides removed from FDA restriction in 2026

---

FAQ

Q: What do the FDA briefing documents say about peptides? A: In the Points to Consider section of its July 2026 briefing document, FDA proposes that each of the seven peptides under review not be included on the 503A Bulks List. The proposal covers both the free base and the acetate form of every substance, which is fourteen entries in total.

Q: Which peptides is the PCAC reviewing in July 2026? A: On July 23, 2026 the committee takes up BPC-157, KPV, TB-500, and MOTS-c. On July 24 it takes up Emideltide (also called DSIP), Epitalon, and Semax. FDA reviewed each substance against a specific proposed use, such as wound healing for TB-500 and insomnia for Epitalon.

Q: Does a PCAC recommendation change peptide access? A: No. Advisory committees give FDA non-binding advice. FDA generally follows that advice but is not legally required to do so, and the agency has said it will not issue a final determination until the advisory process concludes and its reviews are complete.

Q: Why is FDA reviewing peptides whose nominations were withdrawn? A: The briefing document notes that the nominators withdrew several nominations, and that FDA elected to proceed with the presentations anyway. Once a substance is under evaluation, the agency can carry the review forward on its own initiative.

---

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.

---

Sources

• FDA — July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (2026)
• FDA — PCAC Briefing Document Introduction, July 23-24, 2026 (2026)
• FDA — Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (2026)

---